CAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman

Why Is Capricor Therapeutics Stock Falling Friday? - Capricor Therapeutics (NASDAQ:CAPR)

Kaos Capital demands governance reset and cash preservation at Capricor Therapeutics after $80.2M burn in H1 2026 and doubled G&A. Investor pressure for M&A and pipeline diversification reflects skepticism on single-asset valuations; disciplined platforms now biotech market expectation.